top of page


From the start, JMCC has been resolutely focused on meeting the needs of patients, with our founding goal of becoming the best grower of medical cannabis in the world. To us, that means producing premium-quality, sustainably grown, cannabis flower and extracts for our licensed customers to provide to their patients and, more recently, pharma-quality psilocybin to support research around the world. We are fully compliant with GACP standards throughout our cultivation operations in Jamaica while our processing centre is GMP certified. Our newest subsidiary, JMCC Life Sciences Europe, operates from a fully EU GMP-certified facility in Malta. We also produce world-class cannabis-based medicines that provide superior safety, bioavailability and dosing control.

Advancing the Potential of Cannabis as Medicine
Foregoing the opportunities created by the legalization of cannabis for recreational use in Canada, we believe that there is still much to be done to advance the potential of cannabis as a treatment for various medical afflictions. Determining which cannabinoids and other compounds – and in what dosages – are most efficacious for different medical conditions, and how to minimize addiction risks and replace more dangerous drugs like opioids, will require further research.

Resolving Challenges
The many challenges to resolve in normalizing the use of cannabis as medicine include addressing overly restrictive legislation and affordability issues that impact patient access, broadening medical school curricula to include the endocannabinoid system and medical cannabis, eliminating the stigma associated with the use of medical cannabis for patients and doctors, and balancing the need for overly complex and expensive randomized control trials with decades of real-world evidence from millions of medical users.  

At JMCC, we’re helping to answer many of these questions and resolve many of these challenges. We provide medical cannabis for select clinical trials and observational studies in Canada and abroad free or at cost, including initiatives like Project Twenty21, at cost.

bottom of page